Literature DB >> 2712601

The value of second-look operation in patients with advanced epithelial ovarian carcinoma.

P Sevelda1, C Dittrich, H Salzer.   

Abstract

A second-look operation was performed on 151 patients with stage III and IV epithelial ovarian carcinoma who had responded to primary surgery and chemotherapy. 19% of the 79 patients who appeared clinically to be free of disease had microscopic recurrences and 23% had macroscopic residual disease at a second-look operation. The 5-year survival rate for patients with no histological and for those with microscopic secondaries at second-look operation were 55% and 35% respectively (P = 0.45). Only patients with well or moderately well differentiated tumors and a small residual tumor mass at first operation had a good prognosis after a second-look operation even without further chemotherapy. Median survival after secondary debulking was 15 to 17 months and was independent in the radicality of the second-look procedure. Outside of clinical trials second-look laparotomy should therefore only be performed as a diagnostic procedure in patients with well or moderately well differentiated tumors who are left with a small residual tumor mass at the time of the first operation. Because this is a group of patients in whom chemotherapy can be discontinued after a negative second-look operation.

Entities:  

Mesh:

Year:  1989        PMID: 2712601     DOI: 10.1007/BF00931377

Source DB:  PubMed          Journal:  Arch Gynecol Obstet        ISSN: 0932-0067            Impact factor:   2.344


  12 in total

1.  Complete remission at laparotomy: still a gold standard in ovarian cancer?

Authors:  J P Neijt; W W ten Bokkel Huinink; M E Van der Burg; A T van Oosterom
Journal:  Lancet       Date:  1986-05-03       Impact factor: 79.321

2.  Survival of patients following secondary cytoreductive surgery in ovarian cancer.

Authors:  J S Berek; N F Hacker; L D Lagasse; R K Nieberg; R M Elashoff
Journal:  Obstet Gynecol       Date:  1983-02       Impact factor: 7.661

3.  Epithelial carcinoma of the ovary:prognostic importance of histologic grade.

Authors:  T G Day; H S Gallager; F N Rutledge
Journal:  Natl Cancer Inst Monogr       Date:  1975-10

4.  Evaluation of survival data and two new rank order statistics arising in its consideration.

Authors:  N Mantel
Journal:  Cancer Chemother Rep       Date:  1966-03

5.  Second-look operations in the planned management of advanced ovarian carcinoma.

Authors:  K S Raju; J A McKinna; G H Barker; E Wiltshaw; J M Jones
Journal:  Am J Obstet Gynecol       Date:  1982-11-15       Impact factor: 8.661

6.  Ovarian cancer recurrences in patients with no macroscopic tumor at second-look laparotomy.

Authors:  L J Copeland; D M Gershenson
Journal:  Obstet Gynecol       Date:  1986-12       Impact factor: 7.661

7.  [Results of the first Austrian multicenter ovarian cancer study: prospective randomized comparison of sequential chemotherapy (adriamycin/cisplatin--vincristine/cyclophosphamide--methotrexate) with 2 standard protocols (adriamycin/cyclophosphamide or adriamycin/cisplatin) in stage III and IV patients].

Authors:  H Salzer; E Gitsch; C Dittrich; P Sevelda; K Karrer; M Schemper; G Stempel-Smekal; M Langer; G Wagner; H Rainer
Journal:  Geburtshilfe Frauenheilkd       Date:  1985-11       Impact factor: 2.915

8.  Second-look laparotomy in managing epithelial ovarian carcinoma.

Authors:  J Dauplat; J P Ferriere; M Gorbinet; M Legros; P Chollet; B Giraud; R Plagne
Journal:  Cancer       Date:  1986-04-15       Impact factor: 6.860

9.  Predictive value of CA 125 antigen levels in second-look procedures for ovarian cancer.

Authors:  J M Niloff; R C Bast; E M Schaetzl; R C Knapp
Journal:  Am J Obstet Gynecol       Date:  1985-04-01       Impact factor: 8.661

10.  Abdominopelvic computed tomography: evaluation in patients undergoing second-look laparotomy for ovarian carcinoma.

Authors:  D E Brenner; M I Shaff; H W Jones; W W Grosh; F A Greco; L S Burnett
Journal:  Obstet Gynecol       Date:  1985-05       Impact factor: 7.661

View more
  2 in total

1.  DNA analysis, chemoresistance testing and hormone receptor levels as prognostic factors in advanced ovarian carcinoma.

Authors:  J Schneider; L Edler; W Kleine; M Volm
Journal:  Arch Gynecol Obstet       Date:  1990       Impact factor: 2.344

2.  The role of chemotherapy including ifosfamide for ovarian carcinoma. Austrian Collab. Ovarian Cancer Study Group.

Authors:  K Karrer; H Salzer; P Sevelda; C Dittrich
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.